Variables | PsA | CONTROLS |
---|---|---|
Mean ± SD | Mean ± SD | |
AGE (years) | 53.9 ± 8.9 | 54.23 ± 9.3 |
BMI (kg/m2) | 29.3 ± 4.5) | 24.4 ± 3.4* |
SEX (M: F) | 5: 16 | 5: 16 |
DISEASE DURATION (years) | 11.5 ± 10.2 (Median = 6, IQR: 12) | – |
CRP (mg/l) | ||
 Normal | 16 (94%) |  |
 High | 1 (6%) |  |
Pharmacological therapy | ||
 DMARDs | 6 (30%) |  |
 Biological therapy | 5 (25%) |  |
 DMARDs and Biological therapy | 7 (35%) |  |
Foot pain (0 to 10 points) | 5.6 ± 1.9 | 0.2 ± 0.6* |
Knee pain (0 to 10 points) | 4.7 ± 2.6 | 0.5 ± 1.2* |
Hip pain (0 to 10 points) | 4.8 ± 2.9 | 0.1 ± 0.3* |
Lower back pain (0 to 10 points) | 5.4 ± 2.7 | 1.6 ± 2.5* |
Foot function Index | ||
 FFI-Pain (%) | 55.7 ± 18.3 | – |
 FFI-Disability (%) | 44.6 ± 22.7 | |
 FFI-Activity limitation (%) | 34.3 ± 24.4 | |
 FFI-Total (%) | 47.02 ± 18.3 | |
Pain sites |  | – |
 Toes | 15 (71%) |  |
 Metatarsals | 16 (76%) |  |
 Heels | 11 (52%) |  |
 Ankles | 17 (81%) |  |
Deformities |  | – |
 Rearfoot valgus | 13 (62%) |  |
 Hallux valgus | 5 (24%) |  |
 Hallux rigidus | 4 (19%) |  |
 Hammer/claw toes | 14 (67%) |  |